Suppr超能文献

极低卡路里生酮饮食:肥胖合并轻度肾功能衰竭患者减肥的安全有效手段。

Very Low-Calorie Ketogenic Diet: A Safe and Effective Tool for Weight Loss in Patients With Obesity and Mild Kidney Failure.

机构信息

Nephrology and Dialysis Unit, Santa Maria alla Gruccia Hospital, 52025 Arezzo, Italy.

Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome, 00128 Rome, Italy.

出版信息

Nutrients. 2020 Jan 27;12(2):333. doi: 10.3390/nu12020333.

Abstract

Very low-calorie ketogenic diets (VLCKD) are an effective and increasingly used tool for weight loss. Traditionally considered high protein, ketogenic diets are often looked at with concern by clinicians due to the potential harm they pose to kidney function. We herein evaluated the efficacy and safety of a VLCKD in patients with obesity and mild kidney failure. A prospective observational real-life study was conducted on ninety-two patients following a VLCKD for approximately 3 months. Thirty-eight had mild kidney failure and fifty-four had no renal condition and were therefore designated as control. Anthropometric parameters, bioelectrical impedance and biochemistry data were collected before and at the end of the dietary intervention. The average weight loss was nearly 20% of initial weight, with a significant reduction in fat mass. We report an improvement of metabolic parameters and no clinically relevant variation regarding liver and kidney function. Upon stratification based on kidney function, no differences in the efficacy and safety outcomes were found. Interestingly, 27.7% of patients with mild renal failure reported normalization of glomerular filtrate after dietary intervention. We conclude that, when conducted under the supervision of healthcare professionals, a VLCKD is an effective and safe treatment for weight loss in patients with obesity, including those affected by mild kidney failure.

摘要

极低卡路里生酮饮食(VLCKD)是一种有效的、应用日益广泛的减肥工具。由于生酮饮食可能对肾功能造成损害,传统上被认为高蛋白的生酮饮食常常引起临床医生的关注。在此,我们评估了 VLCKD 在肥胖合并轻度肾功能衰竭患者中的疗效和安全性。对 92 例接受 VLCKD 治疗约 3 个月的患者进行了前瞻性观察性真实世界研究。其中 38 例为轻度肾功能衰竭,54 例无肾脏疾病,因此被指定为对照组。在饮食干预前后收集了患者的人体测量参数、生物电阻抗和生化数据。平均体重减轻了初始体重的近 20%,脂肪量显著减少。我们报告代谢参数得到改善,且肝肾功能无临床相关变化。根据肾功能进行分层后,疗效和安全性结果无差异。有趣的是,27.7%的轻度肾功能衰竭患者在饮食干预后肾小球滤过率恢复正常。我们得出结论,在医疗保健专业人员的监督下,VLCKD 是肥胖患者(包括轻度肾功能衰竭患者)减肥的有效且安全的治疗方法。

相似文献

引用本文的文献

本文引用的文献

3
Medical Devices in Obesity Treatment.
Curr Diab Rep. 2019 Aug 30;19(10):90. doi: 10.1007/s11892-019-1217-3.
4
Impact of bariatric surgery on serum uric acid levels and the incidence of gout-A meta-analysis.
Obes Rev. 2019 Dec;20(12):1759-1770. doi: 10.1111/obr.12940. Epub 2019 Aug 30.
6
Primary Care Interventions for Obesity: Review of the Evidence.
Curr Obes Rep. 2019 Jun;8(2):128-136. doi: 10.1007/s13679-019-00341-5.
7
Weight Loss Medications in the Treatment of Obesity and Hypertension.
Curr Hypertens Rep. 2019 Feb 12;21(2):16. doi: 10.1007/s11906-019-0915-1.
8
Evidence for the efficacy and safety of herbal weight loss preparations.
J Integr Med. 2019 Mar;17(2):87-92. doi: 10.1016/j.joim.2019.01.009. Epub 2019 Jan 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验